2020年泌尿系统肿瘤进展.pptx

泌尿系统肿瘤治疗的进展（泌尿上皮癌+前列腺癌）主要内容尿路上皮癌：LAB1、5000前列腺癌：5503、5505、5500、5504肾癌：5001、5002、5003、5004、5005、5006、5007、5008主要内容尿路上皮癌：5000、LAB1前列腺癌：5503、5505、5500、5504肾癌：5001、5002、5003、5004、5005、5006、5007、5008Presentation #4500Atezolizumab as 1L Therapy in Cisplatin- Ineligible Locally Advanced/Metastatic Urothelial Carcinoma: IMvigor210 Cohort 1Arjun Vasant Balar, Matt D. Galsky, Yohann Loriot, Nancy Ann Dawson, Andrea Necchi, Sandy Srinivas, Richard Wayne Joseph, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Alexandra Drakaki, Ignacio Duran, Jonathan E. Rosenberg, Thomas Powles, Jean H. Hoffman-Censits, Na Cui, Sanjeev Mariathasan, Ann Christine Thastrom, Oyewale O. Abidoye, Dean F. Bajorin; Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY; Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France; Lombardi Comprehensive Cancer Center, Washington, DC; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Stanford University Medical Center, Stanford, CA; Mayo Clinic, Jacksonville, FL; Karmanos Cancer Institute, Detroit, MI; Princess Margaret Cancer Centre, Toronto, ON, Canada; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Westwood Rheumatology, Los Angeles, CA; Hospital Universitario Virgen del Rocoí , Seville, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Barts Cancer Institute, Barts Health, and The Royal Free London NHS Foundation Trust, London, United Kingdom; The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Genentech, Inc., South San Francisco, CA; Genentech, Inc., San Mateo, CA; Genentech, Inc., San Francisco, CAIMvigor210 Study: Cohort 1Efficacybr /Overall Survival (Median and Landmark 12-Month OS)不能耐受顺铂治疗的转移性泌尿上皮癌Atezolizumab一线治疗有持久的反应率ORR：24%，无论PD-L1表达高低都可观察到疗效中位随访时间14.4m， 21/28（75%）持续有效CR： 7%所有病人中位生存14.8mAtezolizumab可耐受，治疗相关3/4级毒性和因为AE终止均比较低At